The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multi-center, retrospective study of first-line systemic therapy ± immune checkpoint inhibition for metastatic neuroendocrine carcinoma of the urinary tract.
 
Katharine A. Collier
Research Funding - Conquer Cancer Foundation
 
Nicholas I. Simon
No Relationships to Disclose
 
Amy K Taylor
No Relationships to Disclose
 
Gregory Hemenway
No Relationships to Disclose
 
Tracy L Rose
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GeneCentric (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Corbin Jeffrey Eule
No Relationships to Disclose
 
Nishita Tripathi
No Relationships to Disclose
 
Christopher Rodman
No Relationships to Disclose
 
Uttam Kalluri
No Relationships to Disclose
 
Muhammad Zain Farooq
No Relationships to Disclose
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Exelixis; Janssen; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Sorrento Therapeutics; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)
 
Rohit K. Jain
Honoraria - Curio Science; DAVA Oncology; NCCN/Pfizer; OncLive/MJH Life Sciences
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Gilead Sciences; Gilead Sciences; Pfizer; Seattle Genetics/Astellas
Speakers' Bureau - Gilead Sciences; Seagen; Seattle Genetics/Astellas
Research Funding - Bristol Myers Squibb; Gilead Sciences; NCI
 
Guru P. Sonpavde
Employment - Myriad Genetics (I)
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Merck; Pfizer; Scholar Rock; Seagen
Speakers' Bureau - Medscape; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Janssen (Inst); Predicine (Inst); QED Therapeutics (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bristol-Myers Squibb; Debiopharm Group; Elsevier; G1 Therapeutics; Mereo BioPharma; QED Therapeutics
 
Randy F. Sweis
Stock and Other Ownership Interests - Abbvie (I)
Honoraria - AVEO; Bristol-Myers Squibb/Medarex; Eisai; Exelixis; Seattle Genetics/Astellas
Consulting or Advisory Role - AstraZeneca/MedImmune; AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Janssen Oncology; Mirati Therapeutics; Pfizer; Seattle Genetics/Astellas
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Ascendis Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Eisai (Inst); EpiVax Oncology (Inst); Genentech (Inst); Immunocore (Inst); Jounce Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pionyr (Inst); QED Therapeutics (Inst); Scholar Rock (Inst)
Patents, Royalties, Other Intellectual Property - Neoantigens in Cancer, PCT/US2020/031357
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
 
Elaine T. Lam
Consulting or Advisory Role - Calithera Biosciences
Research Funding - Advaxis (Inst); Amgen (Inst); Argos Therapeutics (Inst); Arrowhead Pharmaceuticals (Inst); Astellas Pharma (Inst); Biosplice (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Constellation Pharmaceuticals (Inst); Decibel Therapeutics (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Harpoon Therapeutics (Inst); Merck (Inst); OnQuality Pharmaceuticals (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Decibel Therapeutics
 
Matthew R. Zibelman
Honoraria - Pfizer
Consulting or Advisory Role - AVEO; Blue Earth Diagnostics; EMD Serono; Exelixis; Janssen; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Horizon Pharma (Inst)
Other Relationship - Association of Community Cancer Centers (ACCC)
 
Hamid Emamekhoo
Consulting or Advisory Role - Cardinal Health; Exelixis; Seagen; Seagen
 
Andrea B. Apolo
No Relationships to Disclose
 
Amir Mortazavi
Honoraria - Motive Medical Intelligence
Consulting or Advisory Role - Debiopharm Group; Pfizer; Seagen
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst)